Search - tctmd.com

Displaying 641 - 660 of 872

Sort: Relevancy | Date

Presentation TCT 2013

When Does Pulmonary Hypertension, RV Dysfunction and/or Tricuspid Regurgitation Derail the Potential for Successful Mitral Valve Intervention?

Presenter: Michael Davidson

October 28, 2013

Presentation TCT 2013

Trying to Assess the Outcomes of Medical and Surgical Therapies for Mitral Regurgitation: Pitfalls in the Literature

Presenter: Blase Carabello

October 28, 2013

Presentation TCT 2013

TCT-129. Percutaneous Transfemoral Management of Severe Secondary Tricuspid Regurgitation with Edwards Sapien XT Bioprosthesis in Patients with Severe Heart Failure: First in Ma...

Presenter: Michael Laule

October 28, 2013

Presentation TCT 2013

TCT-128. Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment of Tricuspid Regurgitation: First-Human-Case Description

Presenter: Hans Figulla

October 28, 2013

Presentation TCT 2013

Similarities and Essential Differences in the US and EU Valve Guidelines for Management of Mitral Regurgitation

Presenter: Alec Vahanian

October 28, 2013

Presentation TCT 2013

Reduces Paravalvular Regurgitation

Presenter: Rebecca Hahn

October 28, 2013

Presentation TCT 2013

Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter Approaches and Outcomes

Presenter: Dominique Himbert

October 28, 2013

Presentation TCT 2013

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Presenter: Samir Kapadia

October 28, 2013

Presentation TCT 2013

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Presenter: Raj Makkar

October 28, 2013

Presentation TCT 2013

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Presenter: Hans Figulla

October 28, 2013

Presentation TCT 2013

Are Medical Therapies Beneficial in Functional Mitral Regurgitation? A Critical Appraisal

Presenter: Robert Bonow

October 28, 2013

Presentation TCT 2013

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Jonathon Leipsic

October 28, 2013

News Conference News TCT 2013

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

October 28, 2013

News Industry News

Boston Scientific Receives CE Mark For Lotus™ Valve System

October 28, 2013

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

Presentation TCT 2013

Hemodynamics and Interactive Calculations for Mitral Stenosis and Mitral Regurgitation using the “John Madden” Telestrator

Presenter: Tim Lapp

October 27, 2013

Presentation TCT 2013

Mitral Regurgitation

Presenter: John Webb

October 27, 2013

News Daily News

MitraClip Gains FDA Approval for Nonsurgical Patients

October 25, 2013

News Industry News

Abbott's First-In-Class MitraClip® Device Now Available for U.S. Patients

October 25, 2013

News Daily News

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

October 11, 2013

Advertisement

When Does Pulmonary Hypertension, RV Dysfunction and/or Tricuspid Regurgitation Derail the Potential for Successful Mitral Valve Intervention?

Trying to Assess the Outcomes of Medical and Surgical Therapies for Mitral Regurgitation: Pitfalls in the Literature

TCT-129. Percutaneous Transfemoral Management of Severe Secondary Tricuspid Regurgitation with Edwards Sapien XT Bioprosthesis in Patients with Severe Heart Failure: First in Ma...

TCT-128. Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment of Tricuspid Regurgitation: First-Human-Case Description

Similarities and Essential Differences in the US and EU Valve Guidelines for Management of Mitral Regurgitation

Reduces Paravalvular Regurgitation

Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter Approaches and Outcomes

Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Case 1: TAVR with a Next Generation Device: Multiple Repositioning and Less Paravalvular Aortic Regurgitation?

Are Medical Therapies Beneficial in Functional Mitral Regurgitation? A Critical Appraisal

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Long-Term Outcomes, Cost May Influence Use of TAVR in Moderate-Risk Patients

Boston Scientific Receives CE Mark For Lotus™ Valve System

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Hemodynamics and Interactive Calculations for Mitral Stenosis and Mitral Regurgitation using the “John Madden” Telestrator

Mitral Regurgitation

MitraClip Gains FDA Approval for Nonsurgical Patients

Abbott's First-In-Class MitraClip® Device Now Available for U.S. Patients

TAVR Patients with Moderate/Severe Mitral Regurgitation Carry Worse Prognosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content